found that HAART use for >4 years was associated with a marginally significant protective effect (OR, 0.28 [95% CI, 0.07–1.06]) on progression from <AIN 2 to AIN 2/3 assessed by HRA while Chiao et al., analyzing the Veterans Administration HIV Clinical Case Registry, found higher proportion of followup time with undetectable HIV plasma viral load predicted lower incidence of IAC.
← all excerpts
Natural history of anal dysplasia in an HIV-infected clinical care cohort: estimates using multi-state Markov modeling.
1
—
—